Uveitis specialists and rheumatologists differ significantly in their most-selected first-choice treatment option for patients with anterior scleritis, according to new findings from a survey by researchers at the University of Colorado.
“[Since] data from controlled trials to guide management are scarce, differences in treatment paradigms [are] possible,” researchers indicated.
The researchers surveyed 1044 uveitis specialists and rheumatologists; a total of 92 responding (8.6%). Those respondents answered questions on first and second choice therapies, and re-select therapies, assuming that the costs of all options were equal and that insurance approval was ensured.
Methotrexate was the most selected first-choice treatment for 78.6% of rheumatologists, compared with 44.4% of uveitis specialists (P <.009). Mycophenolate was the most selected first-choice treatment for 27.8% of uveitis specialist and just 5.3% of rheumatologists (P < .015).
The authors noted that controlled trial data is lacking in management guidance for anterior scleritis. They concluded that treatment preferences are impacted more by specialty than by cost/insurance.
Ozzello DJ, Kolfenbach JR, Palestine AG. Uveitis specialists and rheumatologists select different therapies for idiopathic non-necrotizing anterior scleritis. Ophthalmol Ther. 2016 Oct 15. doi: 10.1007/s40123-016-0067-1 [Epub ahead of print]
This article originally appeared on MPR